The acceptability of presymptomatic testing in 21 people at 50% risk for the APP-692 mutation causing presenile Alzheimer's disease or cerebral haemorrhage resulting from cerebral amyloid angiopathy (FAD-CH), and in 43 people at 50% risk for hereditary Pick disease (HPD) was assessed. Neither group differed in demographic variables. Thirty-nine people (64%) in the whole group would request presymptomatic testing if it were clinically available, although two-thirds did not yet feel ready to take it. The most important reasons in the HPD and FAD-CH group for taking the test were: to further basic research (42% and 47%, respectively), informing children (47% and 50%, respectively), future planning (29% and 47%, respectively), and relieving uncertainty (46% and 27%, respectively).
Abstract
The acceptability of presymptomatic testing in 21 people at 50% risk for the APP-692 mutation causing presenile Alzheimer's disease or cerebral haemorrhage resulting from cerebral amyloid angiopathy (FAD-CH), and in 43 people at 50% risk for hereditary Pick disease (HPD) was assessed. Neither group differed in demographic variables. Thirty-nine people (64%) in the whole group would request presymptomatic testing if it were clinically available, although two-thirds did not yet feel ready to take it. The most important reasons in the HPD and FAD-CH group for taking the test were: to further basic research (42% and 47%, respectively), informing children (47% and 50%, respectively), future planning (29% and 47%, respectively), and relieving uncertainty (46% and 27%, respectively).
The most commonly cited effect of an unfavourable test result concerned increasing problems for spouses (75% and 76%, respectively) and children (61% and 57%, respectively). Most respondents denied that an unfavourable result would have adverse effects on personal mood or relationship. One-third of all respondents favoured prenatal testing where one of the parents had an increased risk for HPD or FAD-CH. Participants would encourage their offspring to have the test before starting a relationship (35%) and before family planning (44%). Thirty-seven percent of the respondents would encourage their children to opt for prenatal diagnosis. People at risk for HPD were significantly more preoccupied with the occurrence of potential symptoms in themselves, compared with those at risk for FAD-CH, reflecting the devastating impact that disinhibition in the affected patient has on the family. Our findings underline the need for adequate counselling and the availability ofprofessional and community resources to deal with the impact of test results in subjects and their relatives. An increasing number of neurodegenerative diseases have been defined at the molecular level in recent years, making it possible to determine the genotype precisely before the onset of symptoms. Presymptomatic testing programmes are available for Huntington's disease (HD), hereditary cerebral haemorrhage with amyloid-Dutch type, inherited cerebral ataxia, myotonic dystrophy, and Alzheimer's disease. -6 For other autosomal dominant disorders, the genetic cause will be detected in the near, foreseeable future. Significant progress has been made in unravelling the dynamics of genes and their products. 7 However, effective pharmacological or gene therapy for late onset neurodegenerative disorders is not expected to be available in the immediate future.
In a collaborative programme on neurogenetics in Rotterdam, two studies on early onset dementia are currently being carried out. The first study concerns a family with presenile Alzheimer's dementia and cerebral haemorrhage (FAD-CH). FAD-CH is caused by a mutation in codon 692 of the gene for famyloid precursor protein (fAPP) on chromosome 21.8 Extracellular amyloid plaques, intraneuronal neurofibrillar tangles, and amyloid angiopathy were found in the brains of two FAD-CH patients. Mutations in the ,APP gene account for less than 3% of disease onset before 65 years of age. 8 In a second study, early onset Pick disease was found in three Dutch families with an autosomal dominant transmission pattern over five to seven generations. The typical clinical features in the patients with hereditary Pick disease (HPD) were disinhibition, stereotyped behaviour, roaming, and hyperorality. Frontal and temporal atrophy on CT scan supported the clinical diagnosis in eight, two, and five living patients in the three families, respectively. The diagnosis of HPD was confirmed in each family by pathological examination of the brain in one, 14 , and 15 patients, respectively. Macroscopic examinations showed selective atrophy of the frontal cortex, non-specific changes (neuronal loss, spongiosis, gliosis), and ballooned cells. Evidence was found in these three families for linkage of HPD to chromosome 17.27 HPD and FAD-CH are primary degenerative diseases of the brain, with onset usually in the fourth to sixth decades of life.9-'2 Both conditions have an average age of onset between 40 and 60 years of age. The course in both disorders is variable, with the development of profound dementia ranging from two to 10 years after diagnosis. No specific treatment is available, but the use of palliative treatments is now being explored.
Misdiagnosis of HPD or FAD-CH, such as depression (FAD-CH) or manic states (HPD), may occur in the early stages of the disease and has often led to unsuccessful psychotherapy of couples. The diagnosis of FAD-CH and HPD is psychologically devastating to the partner and his/her offspring, who have seen the patient's parent, sib, or another close relative become progressively disabled. People sometimes incorrectly believe themselves to be at risk because of symptom searching or preoccupation with early signs. Often, "soft" signs, which are not specific for FAD-CH or HPD, are perceived as a precursor of the disease.
Genetic mutational or linkage analysis may confirm the diagnosis in patients with HPD or FAD-CH and could provide presymptomatic testing for at risk subjects. Presymptomatic testing for Huntington's disease is considered as the paradigm for prediction programmes for other late onset neurodegenerative diseases and cancers'3 and should provide the experience necessary to improve pretest and post-test counselling. Before the introduction of the predictive test, attitudinal studies among those at risk for Huntington's disease have shown that the commonly cited reasons for taking the predictive test were the unbearable uncertainty, anticipating the future, and planning a family, but that an unfavourable result might also lead to depressive feelings and suicidal behaviour. Two out of 39 subjects at risk for HPD/FAD-CH (5%), who would undergo presymptomatic testing, indicated in the questionnaire that they might commit suicide after an unfavourable result and nine (23%) stated that they had not resolved this question. All but two indicated that they would seek professional help after an unfavourable test result.
The most commonly cited effect of receiving a decreased risk was a reduction in problems for spouses (70%) and children (54%) and improved planning for their personal future (51 %) and the family's future (49%). Only 13% agreed that a decreased risk would improve the marriage/relationship.
EXPECTED IMPACT ON FAMILY PLANNING
Among the 26 childless people (41%), six persons wished to have children and another seven were uncertain. Three people with offspring would have more children. Six of the nine who wished to have (more) children would take the presymptomatic test. In case ofan unfavourable result, one of them would refrain from having children, three were uncertain about prenatal diagnosis, one would opt for pregnancy termination of a fetus with an increased risk for the disease, and one would not use prenatal testing. Two people were uncertain about taking the presymptomatic test and did not agree with prenatal diagnosis. One did not wish to learn of his or her personal status, but would opt for exclusion testing, that is, excluding whether or not a fetus has received a chromosome from the affected grandparent.
Some participants would encourage their offspring to take the test before starting a relationship (35%), or before planning a family (42%). If an increased risk was found in their adult child, 31% of the respondents would encourage this child to opt for prenatal diagnosis.
The majority of respondents (59%) were against the availability of prenatal testing for Gene localisation and identification are obviously necessary for obtaining information about the aetiology and molecular genetic aspects of early and late onset dementia. Common interests in the insight into the hereditary nature of dementia may contribute to future therapeutic interventions. Half of those at risk in this study mentioned "to help research" as an important motive for participation. Yet the potential burden of participation in pedigree and linkage studies is often underestimated by researchers and medical specialists. Facing the threat of an appalling disease can cause a variety of psychological, legal, and ethical problems for people at risk. In addition, family members may learn about their own risk for the first time through participation. This problem was often the case for the groups at risk for HPD or FAD-CH. In the information sessions, many people did not fully understand all the ramifications ofbeing at risk. Ideas about heredity were only vague and information previously obtained from professionals (neurologist, general practitioner) were often similarly unclear. Most of the participants were accordingly shocked by the information about their own risks. Is it acceptable to recruit relatives for participation in research who may not even suspect that the disease under investigation is genetic, and that they may carry genes potentially harmful to them or their offspring? For some relatives the request for participation was not ominous news because they suspected that the disease was hereditary. Other relatives may have a positive attitude towards research because genetic information may be relevant, for example, for reproductive decisions or informing their children. Refraining from conducting family studies leaves a family ignorant and might prevent members from knowing the potential threat of personal risk. The moral price of such a policy is that family members are denied the possibility of anticipating their future and making general decisions. Obtaining consent, protecting privacy and confidentiality, and safeguarding divergent and conflicting intrafamilial and intergenerational interests present moral challenges to the conduct of sound research. 30 Our experience emphasises that strong collaboration of all disciplines (molecular and clinical geneticist, neurologist, psychologist, medical ethicist, general practitioner) involved is a requirement for conducting genetic studies.
Many people at risk for HPD were preoccupied with early symptoms in themselves which reflected anxiety and great concern about their future, which was different for the FAD-CH group. The disinhibition/restlessness in the affected parent and other affected relatives was often experienced as frightening and overshadowed the lives of many of those at risk for HPD. This fear affected their self-esteem, future prospects, and their relationship with spouses and relatives. Therefore, in the programming and institutional ethical review of pedigree and linkage studies, attention must be paid to the provision of genetic and psychological counselling. Also, familiarity with genetic concepts in all medical disciplines becomes essential and medical curricula must meet such requirements.
Localisation or finding of the gene often results in the clinical application of predictive testing programmes, given the experience with Huntington's disease, polyposis coli, and breast and ovarian cancer. The predictive programme for Huntington's disease was embedded in careful genetic counselling following the international guidelines, and psychological follow up.203132 Although the medical-ethical issues and benefits of predictive testing are still under debate, the widespread application of such testing as a clinical service proceeds for untreatable genetic disorders. It is not known whether alternatives for solving the emotional and decision making problems in people at risk are offered and can be sufficiently met in health care. Predictive programmes may be too easily established as a result of finding a linkage or mutation, without proper ethical reflection or containment in a follow up research experimental condition.
Although genetic counselling often implies being the devil's advocate by discouraging people at risk from undergoing the test for diseases that have no outlook on treatment, the Huntington experience shows that applicants for the test are very determined to have test results, even in those cases where other options of dealing with the threat might be preferable. Weighing the pros and cons of testing is eventually a personal responsibility.
ACCEPTANCE OF PRESYMPTOMATIC TESTING PROGRAMMES
Both FAD-CH and HPD are rare, devastating diseases, yet the majority of participants in this study would take a presymptomatic test if it became available. As with results found in those at risk for Huntington's disease, many denied the potential untoward effects of becoming identified as a gene carrier.263334 Preparation for the future and worry about the spouse were the main reasons for taking the test, in contrast to the HD group where family planning was paramount.26 Because for the HPD/FAD-CH groups the age ofonset is usually much later and the risk increases dramatically as age advances, people at risk for HPD/FAD-CH might consider testing for general planning such as retirement, medical directives, and early diagnosis and appropriate treatment. 24 The purpose of counselling is to safeguard considerable deliberation. Half of the group that considered predictive testing found that testing should also be accessible for minors under 18 Ap- plicants for the predictive test who are in shock or who are depressive, and who are consequently not able to make a well considered, autonomous choice, should not be given access to the test or testing should be postponed. In all cases, extensive pretest counselling is a prerequisite, in which the pros and cons of testing are explored and weighed. It should be investigated whether the suicidal intention is an indication of either a depressive state of mind or of rational considerations. In addition, the counsellor can actively raise the issue of possible adverse reactions to unfavourable test results, with the inclusion of suicide intentions. It should be noted that the experience with testing for Huntington's disease has shown that people at risk who are not able to cope with unfavourable test results exclude themselves from testing (self-exclusion). What if a competent applicant expresses his intentions to commit suicide after unfavourable results? Should access to the test be refused in such cases? Such a policy has certain objections. First, prohibition oftesting ofthose considering suicide would lead to the concealment of suicidal intentions, as was experienced in the HD presymptomatic testing programme. Second, unconditional refusal of access to testing would be a violation of the principle of autonomy. This principle implies the professional respect for the applicant's considerations regarding the consequences of either test result. Moreover, refusal of access to the test has its moral price because this would force test candidates to remain uncertain about their genetic status. Suicide is not immoral and the intention to commit suicide in certain circumstances not unreasonable. Hence, suicide in case of an unfavourable test result is not a priori irrational. Consequently, it is, in our opinion, a priori morally tenable to allow access to a future predictive test if an applicant expresses his intention to commit suicide after unfavourable test results. In conclusion, we recommend that anxieties and expectancies regarding one's fate be openly discussed. Testing may be postponed and additional support offered when needed. It should also be noted that, as clinical experience with Huntington's disease has shown, suicide may become an option in the final stages of the disease, and not as a reaction to an increased risk test result or after onset of the first signs of the disorder.
People who are the first in a family to participate in genetic studies and presymptomatic testing programmes may assume the responsibility for informing their offspring and relatives about the new information. In the families studied, the key person was often the patient's spouse with whom the heredity of the disease was first discussed and who consented by proxy to testing the affected patient. Such proxy consent is acceptable given the potential interests of children and other relatives with regard to certainty about personal risks, or the relevance of differential diagnosis. In addition, confirmation of diagnosis using DNA testing does not conflict with the demented patient's interests. It may be objected, however, that the potential interests of children and other relatives disqualify them as proxy. Therefore, good medical and ethical practice requires close consideration and discussion whether personal interests interfere with being a proxy.
Information on genetic studies may cause emotional upheaval in relatives who are informed and resentment against the informants. Informing and supporting people with this specific mission about these family issues, which are usually unexpected, may stimulate other relatives to appreciate the value of family studies.
The intended uptake of testing among the HPD/FAD-CH groups is similar to the intended uptake in the HD groups at risk. The actual uptake may be much lower given the HD experience,'6 which is illustrated by the finding that only a minority wishes testing immediately upon availability. As in the HD studies, participants at risk for HPD/FAD-CH emphasised the need for extensive pretest counselling and psychological assessment. Again, the group that requires predictive testing should also be informed about alternative ways of dealing with the issues that led to uptake of the test. Psychotherapy or behavioural therapy might help people to cope better with their anxieties. Couples could be supported in exploring other ways of dealing with their wish to have children. Predictive testing programmes seem to be subject to the "technological imperative". Therefore, the counsellor should approach applicants with full respect for their opinions but must also play the role of the devil's advocate when trying to discuss the pros and cons of testing and consideration of alternative coping strategies. However, this requires a closer collaboration of clinical genetics services and instititions of mental health.
Predictive testing for presenile dementia, such as Alzheimer's disease, should be undertaken only in the context of research protocols, using careful neurological and psychological assessments."4 Testing should not run unnoticed in a widespread clinical application without proper previous evaluation of such a service. However, predictive testing is generally considered, by both professionals and potential users, as a clinical service and not as a research protocol, with the consequence of a lack of follow up data, which hampers a thorough medical-ethical evaluation. Obviously, the relevance of mandatory research assessments for the evaluation of predictive testing should be clarified. Consequently, the contribution to the improvement of the clinical service must be convincing. If these requirements are met, people should be encouraged to participate in research assessments, and to adhere to the provisions of a research protocol. This may be an appropriate expectation by those offering presymptomatic testing for HPD or FAD-CH and HPD.
One special issue that was not addressed by the Alzheimer's study group,24 but which needs attention, concerns those at 25% risk, who are asymptomatic grandchildren of affected subjects. Identification of a person at 25% risk as a gene carrier identifies the unaffected, intervening, parent as a carrier of the disease mutation. Moreover, sibs would see their risks increase to 50%. After the identification of the HD gene, recommendations for presymptomatic testing included a statement regarding those at 25% risk. These recommendations stated that extreme care should be exercised when testing a person at risk would inadvertently provide information about another person who has not requested the test. In such cases, every effort should be made by the counsellors and the subjects concerned to provide a satisfactory resolution of this conflict.20 The majority of representatives from lay organisations favoured the opinion that if no consensus could be reached, the right of the person at 25% risk should have priority over the right of the parent not to know. An important argument is that planning a family may be the main reason for young adults to take the test, whereas their unaffected parents see their chances of ever developing HD dramatically decrease after the age of 50. Those at risk for presenile dementia are approaching the mean age of onset after 50 years of age, at a time when their children may start a family (threequarters ofthe grandchildren in the study group are older than 18 years). Thus, we expect more conflict of interests compared with HD and, in line with the HD guidelines, every effort must be made to solve such controversies both at an individual and a family level. The serious dilemma for the counsellor is whose rights and interests should prevail. Should the counsellor give priority to the applicant's right to know or should he deny testing in order to protect an invasion of the relatives' right not to know? Exclusion testing in a person at 25% risk may be a solution, that is, excluding whether or not one has received a chromosome from the affected grandparent. Such an outcome does not change the risk of the parent at 50% risk. However, the initial conflict arises again if the applicant's risk has increased to 50% and he/she wishes full certainty. Obviously, an unequivocal guideline is not Disease, 1995) . The expected use of prenatal diagnosis in HPD/FAD-CH might be even lower. This expected uptake might reflect feelings in the latter group that onset of the disease is generally later.939 These attitudes reflect the painful and thoughtful handling of options by those at risk and make clear the need for human compassion for people who have experienced the tragedy ofthe disease in their families. Hence, the individual request for prenatal diagnosis ought to be appreciated. However, access to prenatal diagnosis for untreatable late onset disorders should be denied to couples who would not consider a selective pregnancy termination, in order to prevent the violation of the future child's right not to know. In the present study, 10 out of 19 couples would opt for prenatal testing but not for selective abortion. This requires prudent counselling of couples before conception, if possible. This may be a task for the general practitioner followed by referral to a clinical genetics department.
Preimplantation genetic diagnosis may become an alternative in the near future. Recently, it has been suggested that preimplantation genetic diagnosis could be used as a method to achieve prevention of untreatable, autosomal dominant late onset disorders in offspring without disclosure of parental genotype. 40 The couple would be told only that their embryos were tested, and that only apparently disease free embryos were replaced. No information would be given which might provide a basis for inferring whether or not any embryos with the mutation were identified. Hence, parents would derive no direct or indirect information about their own genetic risk, while preimplantation diagnosis could reduce the fetal risk to zero. This option could be valuable for parents at risk who prefer not to know their genetic status. It remains to be seen, however, whether this is a realistic alternative. First, the burdens and risks of in vitro fertilisation should not be underestimated. Furthermore, a condition would be to separate those involved in the testing procedure and the counsellor, otherwise it may become impossible to protect the parent's right not to know adequately.
GENETICS AND DISCRIMINATION
Both employers and the health, life, pension, or disability insurance companies may discriminate against people known to have an increased risk for cancer or neurodegenerative diseases.4" The Dutch debate on the person's duty to reveal genetic information to insurance companies, and on exclusion from life insurance of those at risk for HD and myotonic dystrophy, leads us to emphasise the potential harm to carriers of genes for untreatable genetic disorders with delayed onset. Our clinical experience has taught us that most people at risk for a variety of inherited late onset disorders are not aware of the risk of insurance and employment discrimination or tend to underestimate these issues. Some people have requested predictive testing in order to get access to life insurance. This experience underlines the need for further discussion regarding the use of genetic information by insurance companies and employers. We advocate that participants in genetic studies must be extensively informed of the potential hazards, which may lead to withdrawal from the protocol, or to delay testing until arrangements have been made. At the time of our study, much media attention was paid to discrimination based on genetic risks, which might explain why 20% of the participants held the opinion that test results should not be added to the medical records. Local legislation should protect people with a genetic susceptibility so that those at risk feel free to use the options of genetic testing, and scientists can proceed with research.41 Although legal, ethical, biomedical, and psychosocial issues must be extensively addressed in pre-and post-test counselling sessions, we are aware that the informed consent remains unsatisfactory and has many limitations with regard to these issues.
GENETIC RESEARCH AND HEALTH CARE
The increasing number of diseases that can be predicted by genetic testing (with far reaching consequences) raises the question of how genetics services and other medical disciplines can meet the need for careful pre-and post-test counselling and additional support. Although the need is acknowledged and emphasised in every study, the planning and resources required are rarely considered in most countries. This leaves the human aspect of genetics, such as psychological support and evaluation studies, dependent upon external, temporary financial support. Such lack of continuity in patient care and research and dissemination of clinical research findings may greatly endanger the quality of genetic medicine in the future.
Follow up care must provide proper and consistent information and support about the effects of test results on partner relationships and families. General practitioners must be properly informed about the impact of being at high risk on psychological well being. Health care providers must consider the complex psychological, ethical, and social issues in the application of presymptomatic testing. They should be aware of their own feelings of helplessness,42A4 and be careful not to consider the test as the only option. They must be educated on these issues in order to establish adequate support provisions.
Conclusions
The major limitation of this study was the relatively small number of participants. Another bias may be caused by the number of sibs in the study as four different families were involved. Therefore, the results must be considered with caution. The group studied may not be representative of the entire population at risk for presenile dementia. Moreover, the results, with the inclusion of the intention to have predictive testing when available, may have been biased by the extensive psychological attention ofthe researchers that the participants received. An important limitation is that the data were obtained by means of self-report. The disadvantages of self-report data are well known and include possible social desirability bias. Therefore, qualitative studies using observation and interview techniques and case studies conducted by people who are able to observe people at risk and their families objectively can improve the understanding of the observations which will consequently increase the clinical significance.
